Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

441. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) 9022487 1997 03 07 1997 03 07 2013 11 21 0959-8138 314 7076 1997 Jan 25 BMJ (Clinical research ed.) BMJ Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) 253-7 To determine whether (...) treatment with low dose aspirin and heparin leads to a higher rate of live births than that achieved with low dose aspirin alone in women with a history of recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies), lupus anticoagulant, and cardiolipin antibodies (or anticardiolipin antibodies). Randomised controlled trial. Specialist clinic for recurrent miscarriages. 90 women (median age 33 (range 22-43)) with a history of recurrent miscarriage (median number 4

BMJ1997 Full Text: Link to full Text with Trip Pro

442. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. 9174558 1997 06 17 1997 06 17 2015 06 16 0140-6736 349 9065 1997 May 31 Lancet (London, England) Lancet The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial (...) Collaborative Group. 1569-81 Only a few small trials have compared antithrombotic therapy (antiplatelet or anticoagulant agents) versus control in acute ischaemic stroke, and none has been large enough to provide reliable evidence on safety or efficacy. The International Stroke Trial (IST) was a large, randomised, open trial of up to 14 days of antithrombotic therapy started as soon as possible after stroke onset. The aim was to provide reliable evidence on the safety and efficacy of aspirin and

Lancet1997

443. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. 9077376 1997 04 08 1997 04 08 2013 11 21 0028-4793 336 14 1997 Apr 03 The New England journal of medicine N. Engl. J. Med. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. 973-9 Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin (...) decreases the risk. We measured plasma C-reactive protein, a marker for systemic inflammation, in 543 apparently healthy men participating in the Physicians' Health Study in whom myocardial infarction, stroke, or venous thrombosis subsequently developed, and in 543 study participants who did not report vascular disease during a follow-up period exceeding eight years. Subjects were randomly assigned to receive aspirin or placebo at the beginning of the trial. Base-line plasma C-reactive protein

NEJM1997

444. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.

CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. 9186381 1997 06 25 1997 06 25 2015 06 16 0140-6736 349 9066 1997 Jun 07 Lancet (London, England) Lancet CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. 1641-9 Aspirin is effective in the treatment of acute (...) myocardial infarction and in the long-term prevention of serious vascular events in survivors of stroke and myocardial infarction. There is, however, no reliable evidence on the effectiveness of early aspirin use in acute ischaemic stroke. The Chinese Acute Stroke Trial (CAST) was a large randomised, placebo-controlled trial of the effects in hospital of aspirin treatment (160 mg/day) started within 48 h of the onset of suspected acute ischaemic stroke and continued in hospital for up to 4 weeks. The primary

Lancet1997

445. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.

Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. 9219700 1997 07 17 1997 07 17 2013 11 21 0028-4793 337 3 1997 Jul 17 The New England journal of medicine N. Engl. J. Med. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. 148-53 Recurrent fetal loss has been well described in women with antiphospholipid antibodies. Such women also often have other autoantibodies commonly found in patients (...) with systemic lupus erythematosus. Treating them with prednisone and aspirin may reduce the risk of fetal loss. We screened 773 nonpregnant women who had the unexplained loss of at least two fetuses for antinuclear, anti-DNA, antilymphocyte, and anticardiolipin antibodies and for the lupus anticoagulant. Of 385 women with at least one autoantibody, 202 who later became pregnant were randomly assigned in equal numbers to receive either prednisone (0.5 to 0.8 mg per kilogram of body weight per day) and aspirin (100 mg per day

NEJM1997

446. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. 9259652 1997 09 11 1997 09 11 2015 06 16 0140-6736 350 9075 1997 Aug 09 Lancet (London, England) Lancet Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. 389-96 Antiplatelet therapy with aspirin and systematic anticoagulation (...) with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone. In the Coumadin Aspirin Reinfarction Study (CARS), we aimed to find out whether a combination of low-dose warfarin and low-dose aspirin would give superior results to standard aspirin monotherapy without excessive bleeding risk. We used a randomised double-blind study design. At 293 sites, we randomly assigned 8803 patients who had had myocardial infarction, treatment with 160 mg aspirin, 3 mg warfarin

Lancet1997

447. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis Oler A, Whooley M A, Oler J, Grady D Authors' objectives To determine whether treatment (...) with intravenous heparin and aspirin is more effective than treatment with aspirin alone, in preventing myocardial infarction (MI) or death in patients with unstable angina. Searching MEDLINE was searched from January 1966 to September 1995 for articles published in any language using the keywords 'aspirin', 'heparin' and 'unstable angina'. Additonal material was obtained by handsearching of references from identified articles, and by consultation with experts. Study selection Study designs of evaluations

DARE.1996

448. Aspirin Prophylaxis in Pregnancy: Preventive Medication

Aspirin Prophylaxis in Pregnancy: Preventive Medication Immunizations and Chemoprophylaxis: Aspirin Prophylaxis in Pregnancy Immunizations and Chemoprophylaxis Aspirin Prophylaxis in Pregnancy U.S. Preventive Services Task Force 1996 Recommendation There is insufficient evidence to recommend for or against the routine use of aspirin to prevent preeclampsia or intrauterine growth retardation in pregnant women, including those at high risk. ( , 70 KB)

Publication 3261996

449. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. 8918275 1996 12 17 1996 12 17 2015 06 16 0140-6736 348 9038 1996 Nov 16 Lancet (London, England) Lancet A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. 1329-39 Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk (...) of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic

Lancet1996

450. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. 8782752 1996 10 17 1996 10 17 2015 06 16 0140-6736 348 9028 1996 Sep 07 Lancet (London, England) Lancet Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III (...) < or = 25%, previous thromboembolism, systolic blood pressure of more than 160 mm Hg at study enrollment, or being a woman aged over 75 years) were randomly assigned either a combination of low-intensity, fixed-dose warfarin (international normalised ratio [INR] 1.2-1.5 for initial dose adjustment) and aspirin (325 mg/day) or adjusted-dose warfarin (INR 2.0-3.0). Drugs were given open-labelled. The mean INR during follow-up of patients taking combination therapy (n = 521) was 1.3, compared with 2.4

Lancet1996

451. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.

A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. 8973228 1997 01 17 1997 01 17 2013 11 21 0959-8138 313 7070 1996 Dec 07 BMJ (Clinical research ed.) BMJ A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. 1429-31 To compare aspirin with anticoagulation with regard to risk (...) of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction. A multicentre unblinded randomised clinical trial. 38 hospitals in six countries. 1036 patients who had been treated with anistreplase for myocardial infarction were randomly assigned to either aspirin (150 mg daily) or anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant). The trial was stopped earlier than originally intended because of the slowing rate

BMJ1996 Full Text: Link to full Text with Trip Pro

452. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.

Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Lack of effect of aspirin in asym... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1995 ) Volume: 123 , Issue: 9 , Pages: 649-655 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine the effectiveness of aspirin (...) in preventing ischemic events in patients with asymptomatic carotid stenosis. DESIGN: Double-blind, placebo-controlled trial. SETTING: University-affiliated hospitals. PATIENTS: 372 neurologically asymptomatic patients with carotid stenosis of 50% or more in at least one artery as determined by luminal diameter reduction on duplex ultrasonography. INTERVENTION: Patients were randomly assigned to receive either enteric coated aspirin, 325 mg/d, or identically appearing placebo. Duration of therapy

Annals of Internal Medicine1995

453. Aspirin and myocardial infarction

Aspirin and myocardial infarction Aspirin and myocardial infarction Aspirin and myocardial infarction NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Aspirin and myocardial infarction. York: Centre for Reviews and Dissemination (CRD) 1995: 4 Authors (...) ' objectives To summarise the evidence relating to the use of aspirin following myocardial infarction. Authors' conclusions Aspirin as emergency therapy: Aspirin is an effective therapy in patients with acute myocardial infarction. Patients with suspected acute myocardial infarction should receive 150mg aspirin daily. There are very few contraindications for the immediate use of aspirin. Intravenous thrombolytic therapy: Intravenous thrombolytic therapy is also effective in suitable patients. The benefit

Health Technology Assessment (HTA) Database.1995

454. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Gage B, Cardinalli A, Albers G, Owens D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) In the base case analysis, patients were 65 years old, had NVAF and were 'good candidates for warfarin and aspirin therapy'. Setting The economic study was carried out in California, USA. Dates to which data relate Effectiveness and resource use data were taken from a range of studies published between 1989 and 1995. Costs were given in 1994 prices. Source of effectiveness data Estimates of effectiveness were obtained from a review of the previously published studies. Modelling A Markov model was used

NHS Economic Evaluation Database.1995

455. Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality

Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality Hauth J C, Goldenberg R L, Parker C R, Cutter G R, Cliver S P Authors' objectives To determine the association between low-dose aspirin treatment and subsequent abruptio placentae or perinatal (...) mortality. Searching MEDLINE was searched from January 1985 to April 1994, using the headings: 'human pregnancy', 'pregnancy-induced hypertension'. 'preeclampsia', 'aspirin', 'hypertension', 'clinical trials' and 'abruptio placentae'. Reference lists from all retrieved reports, review articles and chapters from textbooks were examined to locate further trials. Only published, English language literature was considered for inclusion. Study selection Study designs of evaluations included in the review

DARE.1995

456. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment

The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment Durongpisitkul K, Gururaj V J, Park J M, Martin C F Authors' objectives To evaluate (...) the efficacy of aspirin (ASA) and/or intravenous immunoglobulin (IVIG) in the prevention of coronary artery aneurysm (CAA) in children with Kawasaki disease. Searching MEDLINE and EMBASE were searched from 1967 to 1993 with the subject heading 'mucocutaneous lymph node syndrome' and subheadings 'coronary aneurysm' and 'coronary artery aneurysm'. Additional articles were identified from bibliographies of retrieved articles. Study selection Study designs of evaluations included in the review Prospective

DARE.1995

457. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. 7491044 1996 01 02 1996 01 02 2015 06 16 0140-6736 346 8989 1995 Dec 09 Lancet (London, England) Lancet Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. 1509-14 In ischaemic stroke, thrombolytic drugs (...) speed the recanalisation of intracerebral arteries. The effects of aspirin are not known. A trial was conducted to determine whether, separately or together, streptokinase and aspirin have clinical benefits in acute ischaemic stroke similar to those in acute myocardial infarction. 622 patients with acute ischaemic stroke within 6 hours of symptom onset were randomised with a 2 x 2 factorial design to (i) a 1-hour intravenous infusion of 1.5 MU streptokinase, (ii) 300 mg/day buffered aspirin for 10

Lancet1995

458. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. 7739307 1995 06 07 1995 06 07 2015 06 16 0140-6736 345 8959 1995 May 13 Lancet (London, England) Lancet Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. 1201-4 Intravenous heparin has been (...) heparin (adjusted dose with partial thromboplastin time 1.5-2 times baseline), and 36 to aspirin (325 mg daily). All had additional conventional antianginal therapy. After the run-in patients were monitored for 3 days. The primary endpoint was reduced myocardial ischaemia assessed by the number of anginal attacks, silent ischaemic episodes, and duration of ischaemia per day. At 1 week and 1 month we accounted for anginal attacks and other clinical events (myocardial infarction, revascularisation

Lancet1995

459. Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia

Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Jonas S Authors' objectives To investigate the effect of aspirin on occurrence of stroke or death in women who have previously suffered cerebral ischaemia. Searching Studies were identified by searching MEDLINE, and English (...) -language medical, neurological and stroke journals; by examining previous meta-analyses; and by discussion with colleagues at international and national stroke meetings. Study selection Study designs of evaluations included in the review Randomised double-blind trials were included. Specific interventions included in the review Aspirin; placebo. Participants included in the review Patients who had suffered transient ischaemia or stroke in the carotid or vertebrobasilar artery territories, were included

DARE.1994

460. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. 7907677 1994 04 20 1994 04 20 2015 06 16 0140-6736 343 8899 1994 Mar 19 Lancet (London, England) Lancet Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. 687-91 Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation (...) , but the value of this agent relative to aspirin in unclear. In the first Stroke Prevention in Atrial Fibrillation (SPAF-I) study, direct comparison of warfarin with aspirin was limited by the small number of thromboembolic events. SPAF-II aims to address this issue and also to assess the differential effects of the two treatments according to age. We compared warfarin (prothrombin time ratio 1.3-1.8, international normalised ratio 2.0-4.5) with aspirin 325 mg daily for prevention of ischaemic stroke and

Lancet1994